---
document_datetime: 2025-12-02 06:13:26
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/silgard.html
document_name: silgard.html
version: success
processing_time: 0.1240787
conversion_datetime: 2025-12-28 11:01:28.559715
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Silgard

[RSS](/en/individual-human-medicine.xml/66359)

##### Withdrawn

This medicine's authorisation has been withdrawn

human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Silgard](#news-on)
- [More information on Silgard](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 18 February 2019, the European Commission withdrew the marketing authorisation for Silgard (human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp &amp; Dohme Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Silgard was granted marketing authorisation in the EU on 19 September 2006 for prevention of diseases caused by specific human papillomavirus (HPV) types: cervical and anal cancer, precancerous or dysplastic lesions in the anus and female genitals, and genital warts. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2011.

Silgard was a duplicate application to Gardasil, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Gardasil and Gardasil 9.

The European Public Assessment Report (EPAR) for Silgard is updated to reflect that the marketing authorisation is no longer valid.

Silgard : EPAR - Summary for the public

English (EN) (556.71 KB - PDF)

**First published:** 11/08/2008

**Last updated:** 02/04/2019

[View](/en/documents/overview/silgard-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-919)

български (BG) (701.82 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/bg/documents/overview/silgard-epar-summary-public_bg.pdf)

español (ES) (579 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/es/documents/overview/silgard-epar-summary-public_es.pdf)

čeština (CS) (636.1 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/cs/documents/overview/silgard-epar-summary-public_cs.pdf)

dansk (DA) (554.76 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/da/documents/overview/silgard-epar-summary-public_da.pdf)

Deutsch (DE) (557.67 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/de/documents/overview/silgard-epar-summary-public_de.pdf)

eesti keel (ET) (550.61 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/et/documents/overview/silgard-epar-summary-public_et.pdf)

ελληνικά (EL) (691.22 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/el/documents/overview/silgard-epar-summary-public_el.pdf)

français (FR) (581.12 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/fr/documents/overview/silgard-epar-summary-public_fr.pdf)

hrvatski (HR) (605.32 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/hr/documents/overview/silgard-epar-summary-public_hr.pdf)

italiano (IT) (554.77 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/it/documents/overview/silgard-epar-summary-public_it.pdf)

latviešu valoda (LV) (661.09 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/lv/documents/overview/silgard-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (608.16 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/lt/documents/overview/silgard-epar-summary-public_lt.pdf)

magyar (HU) (655.15 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/hu/documents/overview/silgard-epar-summary-public_hu.pdf)

Malti (MT) (664.08 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/mt/documents/overview/silgard-epar-summary-public_mt.pdf)

Nederlands (NL) (580.36 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/nl/documents/overview/silgard-epar-summary-public_nl.pdf)

polski (PL) (634.02 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/pl/documents/overview/silgard-epar-summary-public_pl.pdf)

português (PT) (578.72 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/pt/documents/overview/silgard-epar-summary-public_pt.pdf)

română (RO) (584.8 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/ro/documents/overview/silgard-epar-summary-public_ro.pdf)

slovenčina (SK) (664.82 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/sk/documents/overview/silgard-epar-summary-public_sk.pdf)

slovenščina (SL) (652.39 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/sl/documents/overview/silgard-epar-summary-public_sl.pdf)

Suomi (FI) (590.72 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/fi/documents/overview/silgard-epar-summary-public_fi.pdf)

svenska (SV) (554.75 KB - PDF)

**First published:**

11/08/2008

**Last updated:**

02/04/2019

[View](/sv/documents/overview/silgard-epar-summary-public_sv.pdf)

## Product information

Silgard : EPAR - Product Information

English (EN) (1.46 MB - PDF)

**First published:** 25/09/2009

**Last updated:** 02/04/2019

[View](/en/documents/product-information/silgard-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-660)

български (BG) (2.57 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/bg/documents/product-information/silgard-epar-product-information_bg.pdf)

español (ES) (1.55 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/es/documents/product-information/silgard-epar-product-information_es.pdf)

čeština (CS) (2.22 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/cs/documents/product-information/silgard-epar-product-information_cs.pdf)

dansk (DA) (1.45 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/da/documents/product-information/silgard-epar-product-information_da.pdf)

Deutsch (DE) (1.59 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/de/documents/product-information/silgard-epar-product-information_de.pdf)

eesti keel (ET) (1.44 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/et/documents/product-information/silgard-epar-product-information_et.pdf)

ελληνικά (EL) (2.71 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/el/documents/product-information/silgard-epar-product-information_el.pdf)

français (FR) (1.54 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/fr/documents/product-information/silgard-epar-product-information_fr.pdf)

hrvatski (HR) (1.56 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/hr/documents/product-information/silgard-epar-product-information_hr.pdf)

íslenska (IS) (1.47 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/is/documents/product-information/silgard-epar-product-information_is.pdf)

italiano (IT) (1.6 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/it/documents/product-information/silgard-epar-product-information_it.pdf)

latviešu valoda (LV) (2.23 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/lv/documents/product-information/silgard-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.5 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/lt/documents/product-information/silgard-epar-product-information_lt.pdf)

magyar (HU) (2.2 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/hu/documents/product-information/silgard-epar-product-information_hu.pdf)

Malti (MT) (2.32 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/mt/documents/product-information/silgard-epar-product-information_mt.pdf)

Nederlands (NL) (1.61 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/nl/documents/product-information/silgard-epar-product-information_nl.pdf)

norsk (NO) (1.44 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/no/documents/product-information/silgard-epar-product-information_no.pdf)

polski (PL) (2.28 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/pl/documents/product-information/silgard-epar-product-information_pl.pdf)

português (PT) (1.56 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/pt/documents/product-information/silgard-epar-product-information_pt.pdf)

română (RO) (1.58 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/ro/documents/product-information/silgard-epar-product-information_ro.pdf)

slovenčina (SK) (2.2 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/sk/documents/product-information/silgard-epar-product-information_sk.pdf)

slovenščina (SL) (2.13 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/sl/documents/product-information/silgard-epar-product-information_sl.pdf)

Suomi (FI) (1.49 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/fi/documents/product-information/silgard-epar-product-information_fi.pdf)

svenska (SV) (1.49 MB - PDF)

**First published:**

25/09/2009

**Last updated:**

02/04/2019

[View](/sv/documents/product-information/silgard-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS/1349/G 18/02/2019

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Silgard : EPAR - All Authorised presentations

English (EN) (493.13 KB - PDF)

**First published:** 05/09/2007

**Last updated:** 02/04/2019

[View](/en/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-6)

български (BG) (570.4 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/bg/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_bg.pdf)

español (ES) (490.26 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/es/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_es.pdf)

čeština (CS) (550.1 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/cs/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (488.88 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/da/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (481.35 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/de/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (487.32 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/et/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (609.95 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/el/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_el.pdf)

français (FR) (488.1 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/fr/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (485.69 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/it/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (535.39 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/lv/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (527.3 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/lt/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (546.57 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/hu/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (555.36 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/mt/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (492.97 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/nl/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_nl.pdf)

polski (PL) (534.97 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/pl/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_pl.pdf)

português (PT) (484.98 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/pt/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_pt.pdf)

română (RO) (522.22 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/ro/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (534.56 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/sk/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (553.01 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/sl/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (491.71 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/fi/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (491.13 KB - PDF)

**First published:**

05/09/2007

**Last updated:**

02/04/2019

[View](/sv/documents/all-authorised-presentations/silgard-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Silgard Active substance

- human papillomavirus type 6 L1 protein
- human papillomavirus type 11 L1 protein
- human papillomavirus type 16 L1 protein
- human papillomavirus type 18 L1 protein

International non-proprietary name (INN) or common name human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) Therapeutic area (MeSH)

- Papillomavirus Infections
- Uterine Cervical Dysplasia
- Condylomata Acuminata
- Immunization

Anatomical therapeutic chemical (ATC) code J07BM01

### Pharmacotherapeutic group

Vaccines

### Therapeutic indication

Silgard is a vaccine for use from the age of 9 years for the prevention of:

- premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types;
- genital warts (condyloma acuminata) causally related to specific HPV types.

See sections 4.4 and 5.1 for important information on the data that support this indication.

The use of Silgard should be in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/000732 Marketing authorisation holder

Merck Sharp  Dohme Ltd

Hertford Road

Marketing authorisation issued 19/09/2006 Withdrawal of marketing authorisation 18/02/2019 Revision 33

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Silgard : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (804.35 KB - PDF)

**First published:** 25/09/2009

**Last updated:** 02/04/2019

[View](/en/documents/procedural-steps-after/silgard-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Silgard-H-C-732-P46-0081 : EPAR - Assessment Report

Adopted

Reference Number: EMA/420635/2017

English (EN) (751.27 KB - PDF)

**First published:** 18/09/2017

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-h-c-732-p46-0081-epar-assessment-report_en.pdf)

Silgard-H-C-732-A20-1421: EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/762033/2015

English (EN) (1.64 MB - PDF)

**First published:** 18/03/2016

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-h-c-732-a20-1421-epar-assessment-report-article-20_en.pdf)

Silgard-H-C-732-P46-0071.1 : EPAR - Assessment Report

Adopted

Reference Number: EMA/182964/2015

English (EN) (1.9 MB - PDF)

**First published:** 18/03/2015

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-h-c-732-p46-00711-epar-assessment-report_en.pdf)

Silgard-H-C-732-P46-0055 : EPAR - Assessment Report

Adopted

Reference Number: EMA/184046/2015

English (EN) (1.58 MB - PDF)

**First published:** 18/03/2015

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-h-c-732-p46-0055-epar-assessment-report_en.pdf)

Silgard-H-C-732-P46-078 : EPAR - Assessment Report

Adopted

Reference Number: EMA/128923/2015

English (EN) (1.68 MB - PDF)

**First published:** 02/03/2015

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-h-c-732-p46-078-epar-assessment-report_en.pdf)

Silgard-C-H-732-WS-523 : EPAR - Assessment Report - Variation

Adopted

English (EN) (1.31 MB - PDF)

**First published:** 05/08/2014

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-c-h-732-ws-523-epar-assessment-report-variation_en.pdf)

Silgard-H-C-732-WS-472 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/66618/2014

English (EN) (1.29 MB - PDF)

**First published:** 04/06/2014

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-h-c-732-ws-472-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Silgard

Adopted

Reference Number: EMA/CHMP/243055/2014

English (EN) (74.44 KB - PDF)

**First published:** 25/04/2014

**Last updated:** 02/04/2019

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-silgard_en.pdf)

Silgard-H-C-732-P45-47 : EPAR - Assessment Report

Adopted

Reference Number: EMA/363824/2013

English (EN) (607.85 KB - PDF)

**First published:** 21/08/2013

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-h-c-732-p45-47-epar-assessment-report_en.pdf)

Silgard-H-C-732-WS-29 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/928494/2011

English (EN) (999.01 KB - PDF)

**First published:** 16/12/2011

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-h-c-732-ws-29-epar-assessment-report-variation_en.pdf)

Silgard-H-C-732-II-24 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/576183/2010

English (EN) (828.4 KB - PDF)

**First published:** 14/09/2010

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-h-c-732-ii-24-epar-assessment-report-variation_en.pdf)

Silgard-H-C-732-II-18 : EPAR - Assessment Report - Variation

English (EN) (1.28 MB - PDF)

**First published:** 25/09/2009

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-h-c-732-ii-18-epar-assessment-report-variation_en.pdf)

Silgard-H-C-732-II-06 : EPAR - Assessment Report - Variation

English (EN) (896.14 KB - PDF)

**First published:** 10/09/2008

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-h-c-732-ii-06-epar-assessment-report-variation_en.pdf)

Silgard-H-C-732-II-12 : EPAR - Assessment Report - Variation

English (EN) (848.15 KB - PDF)

**First published:** 11/08/2008

**Last updated:** 02/04/2019

[View](/en/documents/variation-report/silgard-h-c-732-ii-12-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Silgard

Adopted

Reference Number: EMEA/CHMP/280938/2008

English (EN) (486.83 KB - PDF)

**First published:** 30/05/2008

**Last updated:** 02/04/2019

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-silgard_en.pdf-0)

## Initial marketing authorisation documents

Silgard : EPAR - Scientific Discussion

English (EN) (535.49 KB - PDF)

**First published:** 13/10/2006

**Last updated:** 13/10/2006

[View](/en/documents/scientific-discussion/silgard-epar-scientific-discussion_en.pdf)

Silgard : EPAR - Procedural steps taken before authorisation

English (EN) (43.21 KB - PDF)

**First published:** 13/10/2006

**Last updated:** 13/10/2006

[View](/en/documents/procedural-steps/silgard-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Silgard

[HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS](/en/news/hpv-vaccines-ema-confirms-evidence-does-not-support-they-cause-crps-or-pots) 20/11/2015

[Review concludes evidence does not support that HPV vaccines cause CRPS or POTS](/en/news/review-concludes-evidence-does-not-support-hpv-vaccines-cause-crps-or-pots) 05/11/2015

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 July 2015](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-6-9-july-2015) 13/07/2015

[EMA to further clarify safety profile of human papillomavirus (HPV) vaccines](/en/news/ema-further-clarify-safety-profile-human-papillomavirus-hpv-vaccines) 13/07/2015

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2014) 25/04/2014

[European Medicines Agency recommends continued vaccination with Gardasil](/en/news/european-medicines-agency-recommends-continued-vaccination-gardasil) 19/02/2009

[European Medicines Agency statement on the safety of Gardasil](/en/news/european-medicines-agency-statement-safety-gardasil) 24/01/2008

#### More information on Silgard

- [Human Papillomavirus1 Type 6 L1 protein / Human Papillomavirus1 Type 11 L1 protein / Human Papillomavirus1 Type 16 L1 protein / Human Papillomavirus1 Type 18 L1 protein - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/human-papillomavirus1-type-6-l1-protein-human-papillomavirus1-type-11-l1-protein-human-papillomavirus1-type-16-l1-protein-human-papillomavirus1-type-18-l1-protein)
- [Human papillomavirus vaccines - Cervarix, Gardasil, Gardasil 9, Silgard - referral](/en/medicines/human/referrals/human-papillomavirus-vaccines-cervarix-gardasil-gardasil-9-silgard)
- [DARWIN EU® Effectiveness of Human Papillomavirus Vaccines (HPV) to prevent cervical cancer - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000080)

**This page was last updated on** 02/04/2019

## Share this page

[Back to top](#main-content)